Thymidylate synthase inhibitors in colorectal cancer

Seminars in Oncology

Volumn 27, Issue 5 SUPPL. 10, 2000, Pages 83-87

  Cassidy, J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; METHYLENETETRAHYDROFOLIC ACID; NOLATREXED; PEMETREXED; PLEVITREXED; RALTITREXED; THYMIDYLATE SYNTHASE INHIBITOR;

ANOREXIA; ASTHENIA; CANCER INHIBITION; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SOLUBILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER TOXICITY; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; ENZYME INHIBITORS; FOLIC ACID; GLUTAMATES; GUANINE; HUMANS; QUINAZOLINES; THIOPHENES; THYMIDYLATE SYNTHASE;

EID: 0033786858     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts
2. Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumours
3. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer
4. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
5. Quantitation of intratumoural thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: Preliminary report from an ongoing trial
6. Thymidylate synthase expression and activity: Relation to S-phase parameters and 5-fluorouracil sensitivity
7. Limited prognostic importance of immunohistochemical parameters in 465 patients with Dukes' B2 and C colon cancer enrolled on North central treatment group trials
8. Prognostic role of thymidylate synthase, p53, p21, Ki67 and BCL-2 for patients with colorectal cancer treated with surgery alone or with adjuvant 5-fluorouracil and levamisole
9. Thymidylate synthase expression from formalin fixed paraffin embedded tissues using quantitative RT-PCR correlates with frozen tissue data and predicts for response to 5-fluorouridine in metastatic colorectal cancer
10. Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex
11. 10-propargyl-5,8-dideazafolic acid, CB3717
12. Tomudex (raltitrexed) development: Preclinical, phase I and II studies
13. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer
14. Final results of a randomised trial comparing Tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
15. Raltitrexed (Tomudex) vs 5-fluorouracil + leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): Results of a randomised multicenter North American trial
16. Mature results from three large controlled studies with raltitrexed (Tomudex)
17. Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (de Gramont, Lokich and raltitrexed) in metastatic colorectal cancer
18. Interaction of Tomudex with radiation in vitro and in vivo
19. LY231514, a pyrollo[2,3-d]pyrimidine based antifolate that inhibits multiple folate requiring enzymes
20. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate
21. A phase II trial of LY231514 in patients with metastatic colorectal cancer
22. Phase II study of the multi-targeted anti-folate (LY231514) (MTA) as first line therapy in patients with locally advanced or metastatic colorectal cancer (MCC)
23. A phase II trial of MTA (multiple targeted antifolate, LY231514) in patients with 5-FU and irinotecan-refractory colorectal cancer
24. Clinical studies with MTA
25. The renal effects of the water soluble, non-folylpolyglutamate synthetasedependent thymidylate synthase inhibitor ZD9331 in mice
26. Phase I and pharmacokinetic study of oral ZD9331, a nonpolyglutamated thymidylate synthase (TS) inhibitor administered once or twice daily for 5 days every 3 weeks
27. Phase I trial of ZD9331, a non-polyglutamatable thymidylate synthase (TS) inhibitor given as a five day continuous infusion every 3 weeks
28. Clinical pharmacokinetic and pharmacodynamic studies with the non-classical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24 hour continuous intravenous infusion
29. Clinical pharmacokinetic and pharmacodynamic studies with the non-classical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumours
30. A phase II trial of thymitaq (AG 337) in patients with adenocarcinoma of the colon